Combination treatment for advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug combined with other anti-cancer drugs for advanced breast cancer. The goal is to see if the combination can shrink tumors and help people live longer, and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your breast cancer is advanced or has spread to other parts of the body.
- You have at least one tumor that can be measured on a scan.
- You are expected to live at least 3 more months.
- Your organs (like liver, kidneys, and bone marrow) are working well enough.
- You have not had cancer treatment (like chemo, radiation, or targeted therapy) in the last 4 weeks, or hormone therapy in the last week.
- Women who could become pregnant must use birth control and have a negative pregnancy test before starting, and avoid pregnancy for 7 months after treatment.
- Men who are not sterile must use birth control with their partner for 7 months after treatment.
- You must be willing and able to sign a consent form and follow the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests a new drug (SHR2554) combined with standard hormone therapy for people with advanced or metastatic breast cancer. The goal is to see if the combination helps control the cancer better.
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This study tests a new combination of three drugs for advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow down the cancer's growth.
This trial tests whether adding two newer drugs to standard chemotherapy can improve outcomes for women with early-stage breast cancer that is hormone-receptor positive and has low HER2. The goal is to see if a combination of immunotherapy and targeted therapy helps shrink tumors before surgery.
This trial tests two drugs combined—SHR-1501 and adbelizumab—for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and effective.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.